Shares in the Danish pharmaceutical giant Novo Nordisk fell by 10% after the drugmaker announced its oral semaglutide failed to show benefits in slowing the progression of Alzheimer’s disease.
Semaglutide, the active ingredient in Novo’s blockbuster diabetes and weight loss drugs Ozempic and Wegovy, was tested for two years in phase 3 trials, involving 3,808 adults with early signs of Alzheimer’s disease, to see its effects compared with a placebo.
